Umuntu EML4-ALK Fusion Gene Mutation

Iki gikoresho gikoreshwa mugushakisha neza ubwoko 12 bwimiterere ya EML4-ALK fusion gene mubitegererezo byabarwayi ba kanseri yibihaha itari mito mito muri vitro. Ibisubizo by'ibizamini ni ibyavuzwe gusa kandi ntibigomba gukoreshwa nk'ishingiro ryonyine ryo kuvura abarwayi ku giti cyabo. Abaganga b’amavuriro bagomba gufata imyanzuro yuzuye ku bisubizo by’ibizamini hashingiwe ku bintu nk’umurwayi umeze, ibimenyetso by’ibiyobyabwenge, igisubizo cy’ubuvuzi, n’ibindi bipimo bya laboratoire. Kanseri y'ibihaha ni ikibyimba kibi cyane ku isi, kandi 80% ~ 85% by'abanduye ni kanseri y'ibihaha itari ntoya (NSCLC). Gene fusion ya echinoderm microtubule ifitanye isano na poroteyine isa na 4 (EML4) na anaplastique lymphoma kinase (ALK) ni intego yibitabo muri NSCLC, EML4 na ALK biri mubantu bande P21 na P23 kuri chromosome 2 kandi bitandukanijwe na miriyoni 12.7. Nibura habonetse impinduka 20 zo guhuza, muri zo 12 za fusion zo mu mbonerahamwe ya 1 zirasanzwe, aho mutant 1 (E13; A20) ari yo ikunze kugaragara cyane, ikurikirwa na mutant 3a na 3b (E6; A20), bingana na 33% na 29% by’abarwayi bafite EML4-ALK fusion gene NSCLC. ALK inhibitor ihagarariwe na Crizotinib ni imiti ya molekile ntoya yibasiwe na mutation ya ALK gene fusion. Muguhagarika ibikorwa byakarere ka ALK tyrosine kinase, guhagarika inzira yacyo yo hepfo yerekana inzira zidasanzwe zerekana ibimenyetso, bityo bikabuza gukura kwingirangingo yibibyimba, kugirango bigere kumiti igamije kubyimba. Ubushakashatsi ku mavuriro bwerekanye ko Crizotinib ifite igipimo kirenga 61% ku barwayi bafite ihindagurika rya EML4-ALK, mu gihe nta ngaruka bigira ku barwayi bo mu gasozi. Kubwibyo, gutahura ihinduka rya EML4-ALK fusion ni ishingiro nishingiro ryo kuyobora ikoreshwa ryibiyobyabwenge bya Crizotinib.